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Background: The prevalence of alcohol and other psychoactive substances is high in biological specimens from
injured drivers, while the prevalence of these psychoactive substances in samples from drivers in normal traffic is
low. The aim of this study was to compare the prevalence of alcohol and psychoactive substances in drivers
admitted to hospital for treatment of injuries after road traffic accidents with that in drivers in normal traffic, and
calculate risk estimates for the substances, and combinations of substances found in both groups.
Methods: Injured drivers were recruited in the hospital emergency department and drivers in normal conditions
were taken from the hospital catchment area in roadside tests of moving traffic. Substances found in blood
samples from injured drivers and oral fluid samples from drivers in moving traffic were compared using equivalent
cut off concentrations, and risk estimates were calculated using logistic regression analyses.
Results: In 21.9% of the injured drivers, substances were found: most commonly alcohol (11.5%) and stimulants
eg. cocaine or amphetamines (9.4%). This compares to 3.2% of drivers in normal traffic where the most commonly
found substances were z-hypnotics (0.9%) and benzodiazepines (0.8%). The greatest increase in risk of being injured
was for alcohol combined with any other substance (OR: 231.9, 95% CI: 33.3- 1615.4, p < 0.001), for more than three
psychoactive substances (OR: 38.9, 95% CI: 8.2- 185.0, p < 0.001) and for alcohol alone (OR: 36.1, 95% CI: 13.2- 98.6,
p < 0.001). Single use of non-alcohol substances was not associated with increased accident risk.
Conclusion: The prevalence of psychoactive substances was higher among injured drivers than drivers in normal
moving traffic. The risk of accident is greatly increased among drivers who tested positive for alcohol, in particular,
those who had also ingested one or more psychoactive substances. Various preventive measures should be
considered to curb the prevalence of driving under the influence of psychoactive substances as these drivers
constitute a significant risk for other road users as well as themselves.
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Psychoactive substances are prevalent in emergency de-
partment samples of injured drivers, and several studies
have found high prevalence rates not only of alcohol but
also of medicinal and illicit drugs [1-3]. Studies of dri-
vers in normal moving traffic have shown lower preva-
lence rates [4-6]. In line with this, case–control studies
have demonstrated that presence of psychoactive sub-
stances in drivers is associated with an elevated risk of* Correspondence: StigTore.Bogstrand@fhi.no
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distribution, and reproduction in any mediumtraffic injuries [7-10]. The elevated risk can be explained
by the impairing effects of psychoactive substances on
driving ability (see for instance [11]). In this study we
apply a case–control design to address psychoactive sub-
stance use and non-fatal traffic injuries.
Several types of methodological weaknesses hamper
many of the case–control studies that have assessed the
relative risk of psychoactive substance use for traffic in-
juries. These comprise non-representative samples of
controls (e.g. other patients) and non-equivalent bio-
logical samples for cases and controls ([7]). In an ideal
situation controls should be random drivers in normal
traffic and blood samples should be collected from both
cases and controls, as blood is the biological sample thattral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Bogstrand et al. BMC Public Health 2012, 12:734 Page 2 of 9
http://www.biomedcentral.com/1471-2458/12/734best reflects the drug concentrations in the central ner-
vous system (CNS). Earlier case–control studies of psy-
choactive substance use and non-fatal traffic accidents
have not been performed in an ideal situation. Mura and
co-workers used blood samples from both cases and
controls, but the controls were not random drivers in
normal traffic [9], which implies a possible selection bias
in the control group. In the study by Movig and co-
workers controls were sampled from drivers in normal
traffic, but blood samples were compared with urine
samples [8]. As psychoactive substances have longer de-
tection times in urine than in blood [12] their presence
in urine does not necessarily reflect impaired driving.
Comparisons of blood and urine samples can therefore
bias the relative risk estimates downwards.
The ideal situation with bloods samples from controls
in normal moving traffic is, however, very difficult to ob-
tain. It is costly to obtain a sufficiently large sample of
random drivers in normal traffic and it is difficult to col-
lect blood samples in normal moving traffic. Drivers
may be reluctant to participate in roadside studies and
to give blood samples, even with monetary incentives
[13]. Encouraging high levels of participation is very im-
portant as the total prevalence may be as low as 4.5% or
less for both alcohol and other psychoactive substances
among drivers in moving traffic [4-6].
One way of overcoming the problem with collection of
blood samples in random drivers is to use oral fluid for
drug screening in moving traffic. Collection of oral fluid
has proved successful in random drivers, with low re-
fusal rates [5]. Oral fluid can be compared to blood sam-
ples as both specimen types are positive for drugs for
the same average length of time after intake of a single
dose. The distribution of drug concentrations in oral
fluid reflects the distribution of drug concentrations in
blood in a population [14]. Comparisons between blood
samples and oral fluid samples can be made if equivalent
cut-off concentrations in blood and oral fluid are used
[14]. One previous case–control study has compared
psychoactive substances in cases and random driver con-
trols applying comparable biological samples (blood and
oral fluid) to assess relative risk estimates for traffic in-
juries [7]. While these estimates were for fatal traffic in-
juries we have in this study applied the same study
design with random driver controls and comparable bio-
logical samples to assess relative risk estimates with re-
spect to non-fatal injuries.
Combinations of drugs are prevalent among injured
drivers [2,3,15] while combinations in moving traffic are
rare [5]. Some studies suggest that combinations of vari-
ous psychoactive substances constitute a particular
increased risk of traffic injuries [8,11]. In line with this, a
recent Norwegian case–control study of fatal road traffic
accidents found few single substance cases in theaccident group but a major increase in risk for drivers
with combinations of psychoactive drugs [7]. It therefore
seems particularly important to assess the impact of
multiple psychoactive substance use on traffic injuries.
The aim of our study was to compare the prevalence
of alcohol and psychoactive drugs in drivers admitted to
hospital for treatment of non-fatal injuries after road
traffic accidents with prevalence in drivers in normal
traffic, and to calculate odds ratios for single and mul-
tiple substance use.
Methods
Study design and setting
This study has a case–control design. Cases were patients
admitted to the regional trauma centre for treatment of
injuries after driving a car involved in an accident. Con-
trols were a large sample of drivers from normal moving
traffic in the hospital catchment area. The hospital is the
trauma centre for the south-eastern part of Norway cov-
ering both urban and rural areas and including the cap-
ital, Oslo. About 2.5 million people live in the catchment
area of the trauma centre. The source population was
drivers in moving traffic in the south-eastern parts of
Norway.
Description of cases
Inclusion of injured drivers
Drivers older than 18 year of age admitted to the emer-
gency department at Oslo University Hospital, Ullevål,
were included. Criteria for inclusion was informed con-
sent from the patient or his or hers next of kin if the pa-
tient was not able to give an informed consent. If the
patient was unavailable to give consent in the emergency
department because of acute medical treatment or for
other reasons, blood samples were obtained and the
patients were asked to give informed consent later dur-
ing the stay. If the patient refused to participate, was dis-
charged before giving consent or for other reasons could
not give an informed consent, the blood sample was
destroyed. No data was registered on non participants.
The data was collected over a 12 month period from De-
cember 2007 to December 2008. Further details on study
inclusion have been published in an earlier paper [1].
Data collection
All patients included in the study filled in a question-
naire comprising gender, age, time of accident and type
of accident. If the patient was not able to fill out the
questionnaire, for example because of injury, an emer-
gency department nurse assisted them. Blood samples
were drawn, together with diagnostic blood samples and
sent to the Norwegian Institute of Public Health (NIPH)
for analysis. The time of blood sampling was recorded
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excluded from this study.
Blood sample analysis
The blood samples were analyzed according to the fo-
rensic toxicology analytical programme using two differ-
ent methods for screening and confirmation analyses of
the drugs. The samples were first screened for ampheta-
mines, cannabis, cocaine metabolites and opiates by an
immunological method [16]. Screening for other drugs
was carried out using high-performance liquid chroma-
tography with mass spectroscopy detection (LC-MS)
[17]. Then, all drug findings were confirmed and quanti-
fied using gas or liquid chromatography with mass spec-
troscopy detection (GC-MS or LC-MS) [17-20]. An
enzymatic dehydrogenase method was used for ethanol
analysis [21]. Analysis was carried out for a total of 20
different substances, constituting all impairing drugs on
the Norwegian market which have been shown to be
linked to increased accident risk [22]. Analytical cut-off
values corresponding to the cut-off used in the DRUID
project (www.druid-project.eu) were used, as described
in Table 1 [23].
Description of controls
Selection of drivers in roadside survey
The selection of drivers of cars and vans (reference
group) was carried out in collaboration with the Mobile
Police Service (MPS) in south-eastern Norway as a part
of the DRUID project. Drivers were selected from April
2008 to March 2009 using a stratified multi-stage cluster
sampling procedure. The first stage consisted of select-
ing regions in south-eastern Norway. The second stage
covered selection of road sites, and dates and times for
the sampling, while the third stage consisted of ran-
domly stopping of cars and vans for routine control of
breath alcohol or driving licence by the MPS. Participa-
tion was voluntary and anonymous. Our study team
asked as many drivers as possible for participation in the
project during two two-hour periods for each study day.
Oral and written information was given to each driver;
information leaflets were available in 12 languages. If
informed consent was given, a sample of oral fluid was
taken and a short questionnaire was filled in. The fol-
lowing data were recorded: gender, age, nationality of
the driver, and type of vehicle. Drivers did not receive
any reward for taking part in the survey.
Sampling of oral fluid
Samples of oral fluid were collected using Statsure Saliva
Sampler™ (Statsure Diagnostic Systems, Framingham
MA, USA). The oral fluid collection pad was placed
under the tongue until the indicator turned blue or for
five minutes in cases where the indicator did not turnblue within a shorter time. The vial was then capped
and labelled with a bar code label identical to the bar
code of the questionnaire. The sample was stored in a
bag at approximately 5°C for a maximum of 6 hours,
and then frozen at about −20°C.Analysis of oral fluid
The amount of collected oral fluid was determined by
weighing, and the dilution with buffer was taken into ac-
count when calculating analytical results expressed in g
per kg or ng per ml of undiluted (native) oral fluid. Sam-
ples of less than 0.2 ml oral fluid were regarded as failed
samples and therefore excluded.
Alcohol was analysed by an automated enzymatic
method using alcohol dehydrogenase [21]. Drug concen-
trations in oral fluid-buffer mixtures were determined by
liquid chromatography – tandem mass spectrometry
[24]. Cut-off concentrations are presented in Table 1.
Samples with drug concentrations above the linearity
limits were diluted and re-analysed.Variables
Variables for cases and controls were compared as
described in Table 2. Time of sampling and time of acci-
dent were compared according to time and season vari-
ables. The time intervals were defined to adjust for
differences in accident rates at daytime and nighttime,
and weekends and weekdays. Adjustment for season was
made to compensate for the considerable variation in
road conditions, e.g. winter with snow and ice. The time
periods and seasons are described in Table 2. Compari-
sons of single substances and of specific combinations
were carried out when they were present in both groups.
Cut- off concentrations in blood was for all substances
except two equal to those used in the DRUID project.
The cut- off limits for flunitrazepam and diazepam was
considered to be high and the legal limits for use when
driving in Norway was used, for these drugs. The legal
limits were equivalent to a blood alcohol concentration
of 0.2 g/L [25]. Cut- off concentrations in oral fluid that
were equivalent to those used for blood were calculated
as described by Verstraete et al. [26].Statistical analysis
Comparisons of cases and controls were computed using
bi-variate cross tables, and statistical significance was
calculated with Pearson’s chi-square or Fishers exact test
when expected count in a group was less than five.
Adjusted odds ratios were computed using multivariate
logistic regression. All analyses were made in PASW 17
(SPSS.inc, Chicago IL). The level of statistical signifi-
cance was p≤ 0.05.
Table 1 Prevalence and cut-off values in whole blood and oral fluids (n =5401)
Case group (Injured drivers (n = 96) Control group (Moving traffic n = 5305)
Substance Cut-off in whole blood Prevalence% (n) Cut-off in oral fluid Prevalence% (n)
Any substance 21.9 (21) 3.2 (169)
Alcohol 0.02 g/kg 11.5 (11) 0.02 g/kg 0.3 (17)
Stimulant drugs ng/mL 9.4 (9) ng/mL 0.5 (25)
Methamphetamine 20 5.2 (5) 410 0.2 (13)
Amphetamine 20 4.2 (4) 360 0.1 (7)
Benzoylecgonine 50 4.2 (4) 95 0.2 (10)
Cocaine 10 2.1 (2) 170 0.1 (4)
MDMA 20 0 270 0.0 (1)
MDA 20 0 220 0
Benzodiazepines ng/mL 7.3 (7) ng/mL 0.8 (43)
Diazepam 57 3.1 (3) 2.0 0.5 (25)
Clonazepam 10 3.1 (3) 1.7 0.1 (6)
Alprazolam 10 3.1 (3) 3.5 0.0 (1)
Flunitrazepam 1.6 2.1 (2) 0.3 0.1 (3)
Oxazepam 50 0 13 0.1 (6)
Nitrazepam 7.0 0 2.0 0.1 (5)
Cannabis (THC) 1.0 ng/mL 3.1 (3) 27 ng/mL 0.7 (39)
Z- Hypnotics ng/mL 2.1 (2) ng/mL 0.9 (49)
Zopiclone 10 2.1 (2) 25 0.9 (49)
Zolpidem 37 0 10 0
Opiates ng/mL 1.0 (1) ng/mL 0.3 (18)
Methadone 10 1.0 (1) 22 0.1 (3)
Morphine 10 1.0 (1) 95 0.0 (1)
Codeine 10 0 94 0.2 (13)
Heroin (6-MAM) 10 0 16 0.0 (1)
Combinations with alcohol
Alcohol and other psychoactive substance(−s) 4.2 (4) 0 (2)
Positive samples with no alcohol
1 non- alcohol substance 3.1 (3) 2.5 (132)
2 non- alcohol substances 4.2 (4) 0.3 (16)
3 or more non- alcohol substances 3.1 (3) 0.1 (4)
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The inclusion of the injured patients and the drivers in
the roadside survey was approved by the Norwegian data
inspectorate and the regional ethics committee. The
study invitation and consent is described above.
Results
Participants
The case group was a sub-sample of a study including all
patients admitted with injuries. Data were collected over a
12 month period from a large hospital emergency depart-
ment (see Bogstrand et al., 2011 for further details). The
case group consisted of 96 drivers admitted within sixhours of injury (Table 2). The study of injured patients
had no permission to collect data on non-participants. No
information was therefore available on the distribution of
drivers in the non- participant group. The refusal rate for
the whole study was 7% and 24% were not invited to par-
ticipate for other reasons described elsewhere [1]. The
control group consisted of 5305 drivers, with a refusal rate
of 6.2%. Six of the drivers who refused to participate were
apprehended by the police before study inclusion because
of positive alcohol breathalyzer test. There were no signifi-
cant differences in gender distribution but there were
more controls in the older (35–49 and ≥50 years) age
groups and fewer in the youngest group (17–24). The








Gender X2 = 0.638
Male 76 (73) 72 (3839) P = 0.424
Female 24 (23) 28 (1466)
Age Groups X2 = 24.507
17-24 23 (22) 9 (481) P < 0.001
25-34 22 (21) 18 (946)
35-49 28 (27) 36 (1890)
> 50 27 (26) 38 (1988)
Sampling Time
Season X2 = 21.276
1 Spring (Mar-May) 23 (22) 34 (1824) P < 0.001
2 Summer (Jun-Aug) 22 (21) 13 (687)
3 Autumn (Sep-Nov) 20 (19) 31 (1643)
4 Winter (Dec-Feb) 35 (34) 22 (1151)
Day and time X2 = 47.346
1 Mon-Fri 04-10 21 (20) 11 (557) P < 0.001
2 Mon-Fri 10- 16 22 (21) 27 (1439)
3 Mon-Thu 16- 22 24 (23) 10 (525)
4 Mon-Thu 22- 04 7 (7) 5 (256)
5 Sat + Sun 04- 10 5 (5) 3 (180)
6 Sat + Sun 10- 16 5 (5) 19 (1026)
7 Fri-Sun 16- 22 7 (7) 18 (967)
8 Fri-Sun 22- 04 8 (8) 7 (355)
aChi- square test.







Alcohol alone 29.0 (11.5- 73.0)** 36.1 (13.2- 98.6)**







No non-alcohol psychoactive substances (referent)
One psychoactive substance 1.6 (0.5- 5.0)(ns) 1.4 (0.4- 4.4)(ns)
Two psychoactive substances 17.1 (5.6- 52.4)** 13.3 (4.2- 41.3)**
Three or more psychoactive
substances
51.4 (11.3- 233.5)** 38.9 (8.2- 185.0)**
Chi-square test: (ns) = Not statistically significant, , ** = P < 0.001.
1Adjusted for age group and day and time.
2Adjusted for age group.
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(p< 0.001). There were also statistically significant differ-
ences between cases and controls with respect to season
and time and day (p <0.001) as shown in Table 2.
Prevalence of psychoactive substances
Among all the injured drivers, 21.9% tested positive for
one or more psychoactive substances. The substances
most often found among injured drivers (case-group)
were alcohol (11.5%), illicit stimulants such as ampheta-
mines and cocaine (9.4%) and benzodiazepines (7.3%).
About three percent of the drivers in normal traffic
tested positive for any substance. The most prevalent sub-
stances in moving traffic (control-group) was the hypnotic
medicinal drug zopiclone (0.9%), the second was benzo-
diazepines (0.8%), and the third was cannabis (THC)
(0.7%) (Table 1). Prevalence of psychoactive substances
was higher in the case group than in the control group.
Combinations of up to three or more individual medicinal
or illicit drugs were present in both groups, as was alco-
hol, both alone and combined (Table 1). Combinations ofdrugs were more prevalent than single substance findings
in the case group (11.5%) while single substance use of
non-alcohol drugs was more prevalent in the control
group (Table 1). Among the injured drivers, three of the
four combinations with alcohol consisted of a stimulant
drug (amphetamine, methamphetamine or cocaine) two
of the cases was also combined with a hypnotic (zopiclone
or flunitrazepam). Six of the seven cases who had combi-
nations of non- alcohol drugs had combined benzodiaze-
pines and stimulant drugs.Risk estimates
Crude and adjusted relative risk estimates (in terms of
odds ratios) are presented in Table 3. The variables age,
and time and day were differently distributed in cases
and controls and they were also associated with the
presence of alcohol alone or combined. Therefore, these
variables were entered as co-variates in the multi-variate
analyses of the association between presence of alcohol
and injury risk. Age was the only co- variate associated
with non-alcohol psychoactive substance use, and the
only potential confounder entered in the multivariate
analysis of non-alcohol psychoactive substance use and
injury risk. Distribution of cases and controls differed
significantly by time of accident or sampling time of
control group. No significant association was found be-
tween the time variable and substance findings, the
model was therefore not adjusted for time.
The analyses showed that alcohol was the only psycho-
active substance that, when present alone, elevated the
risk on non-fatal traffic injury statistically significantly
(OR: 36.1, 95% CI: 13.2- 98.6, p < 0.001) (Table 3). The
other two substances that were present alone among
both cases and controls were THC and zopiclone. The
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low in the case group, and no statistically significant as-
sociation with risk of traffic injury was found. However,
compared to drivers with no psychoactive substances
present, the risk of non-fatal traffic injury was statisti-
cally significantly elevated among drivers with two non-
alcohol psychoactive substances present (adjusted OR:
13.3, 95% CI: 4.2- 41.3, p < 0.001) (Table 3) and among
those with three or more non-alcohol psychoactive sub-
stances present (adjusted OR: 38.9, 95% CI: 8.2- 185.0,
p < 0.001) (Table 3). The highest OR for being injured in
an accident was found for those who had both alcohol
and one or more other psychoactive substances present
(adjusted OR: 231.9, 95% CI: 33.3- 1615.4, p < 0.001)
(Table 3).
Discussion
This study revealed high risk estimates for alcohol and
multi-drug use when comparing drivers admitted to the
emergency department for injuries in car accidents with
drivers in normal traffic from the hospital catchment
area. The study found no statistically significant risk
associated with the use of one non-alcohol psychoactive
substance alone.
Other studies have also found significantly increased
risk for accidents associated with the use of alcohol (see
Taylor et al. for a review [27]). For instance, the Grand
Rapids Study in 1964 found BAC levels above 0.04% to
be associated with increased accident rates, and higher
BAC levels gave higher accident rates [28]. Similar find-
ings were published in another American study by
Blomberg and colleagues in 2009 [29]. In the Nether-
lands, Movig and colleagues found that drivers who
tested positive for alcohol (BAC above 0.8 g/l) had an
increased likelihood of being injured in an accident;
OR= 15.5 (95% CI:7.1- 33.9) [8] compared with 36.1
(95% CI:13.2- 98.6) in our study. The higher OR reflects
a lower estimated prevalence of alcohol in the control
group in our study. A previous study has shown that the
prevalence of alcohol above the legal BAC limit in nor-
mal traffic is relatively low in Norway compared to other
European countries [5], which is probably due to the
restrictive BAC limits (0.2 g/kg) and related sanctions
in Norway.
Single use of non-alcohol psychoactive substances was
not statistically significantly associated with injury risk
in our study, which is probably due to the low number
of cases. With a larger case group, it might have been
possible to identify psychoactive non- alcohol single sub-
stances associated with traffic accidents, as this was the
most prevalent finding in the control group. In the
present study, combinations of non- alcohol psycho-
active drugs were more prevalent than single non-
alcohol substances in the case group.Prevalence of stimulant drugs was high in the case
group. In other studies, prevalence of cocaine and
amphetamines was low and no significant risk increase
was found for single use of these substances [8,9].
Stimulant substances and amphetamines in particular
are prevalent in Norwegian drivers apprehended by the
police and the drugs are often found in combination
with other psychoactive substances [30]. No stimulant
substances was found alone in both the case and control
group in this study so it was not possible to calculate an
OR for the association between accident risk and single
stimulant drugs.
The highest relative risk estimate in this study was for
alcohol combined with one or more other psychoactive
substances. Similar findings have been reported in earlier
studies [7,8]. Reviewing the literature on the effect of
cannabis compared with alcohol on driving Sewell and
co-workers [31] concluded that combining alcohol with
marijuana results in impairment even at doses which
would be insignificant were they of either drug alone.
Moreover, any combination of multiple psychoactive
substances was associated with an increased risk of traf-
fic injury. This was also reported by Gjerde and co-
workers (2011).
Strengths and limitations
A major strength of this study was the large control
group. This enabled positive findings of different drugs
and combinations even though the prevalence of psy-
choactive drug use among drivers in normal traffic was
low. Another major strength was that analyses of the
blood and oral fluid samples were performed by a la-
boratory accredited for analyzing psychoactive drugs in
forensic toxicology since 1996. Equivalent cut-off thresh-
olds for oral fluid and blood were used to compare the
data, strengthening the risk estimates. Biological samples
from cases and controls were analyzed for a wide
spectrum of psychoactive substances, thereby allowing
for a better assessment of combinations of psychoactive
substances.
The number of cases was relatively low and conse-
quently the test power for analyses of various specific
substances and combinations of substances was low. Six
drivers were apprehended by the police for drunk driv-
ing and refused to participate in the study; the OR for al-
cohol would have been somewhat lower if these drivers
had been included in the analysis. On the other hand,
blood samples were obtained up to six hours after the
injury, which implies that some cases may be false nega-
tives, in which case the relative risk estimate may be
biased downwards.
The use of blood samples from controls would be better
than oral fluid if the participation rate is high. However,
we expected that using oral fluid with high participation
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rate. A limitation when using oral fluid was the uncer-
tainty in determining cutoff concentrations in oral fluid
that were equivalent to those in blood. In our study, we
used those determined by the DRUID project, which so
far are the best documented equivalent cutoffs. By using
prevalence determinations with equivalent cutoff concen-
trations, the effect caused by inter-individual variations in
oral fluid to blood ratios for drugs are reduced compared
to using average OF/B ratios for estimations of drug con-
centrations in blood based on concentrations in oral fluid.
Driver culpability was not considered and risk esti-
mates might have been higher for culpable drivers.
There were some statistical differences in the distribu-
tion of age and time in the two groups but these differ-
ences were considered minor limitations. A major
limitation was the unknown number of non-responders
in the case group, and the relatively small case group.
The authors have no data suggesting the numbers of
non-respondents in the sub-sample of drivers or the dir-
ection of any possible bias.
Implications
The high prevalence of alcohol in injured drivers and the
significant increase in injury risk when driving under the
influence of alcohol (whether alone or in combination
with other substances) highlight the importance of curb-
ing the extent of such driving. Various alcohol policy strat-
egies are shown to be effective in reducing drunk driving
and traffic crashes. These comprise not only low legal
BAC limit and related sanctions [32,33] but also universal
strategies as high taxes on alcoholic beverages [34] and
high minimum legal age for drinking or purchase [35]. In
Norway these effective strategies are employed to a larger
extent than in most other OECD countries [36], and
therefore other prevention strategies should also be con-
sidered. Multi-component programs with community
mobilization [37] installation of ignition interlocks in
drunk driving offenders’ vehicles [38] and mass media
campaigns combined with high visibility enforcement [39]
are strategies that are shown to be effective and therefore
seem particularly relevant in this respect.
The latter type of strategy may also be relevant with re-
spect to other substances than alcohol. An Australian
study of ecstasy users found risk perception to be corre-
lated with driving under the influence (DUI) of alcohol
or other drugs [40]. The users who reported DUI did not
perceive their driving to be impaired and believed that
there was a low accident risk and a low risk of being
apprehended by the police. Therefore, more information
about the actual increase in injury risk with DUI and
more visible enforcement may encourage individuals not
to drive under the influence of psychoactive substances.
Driving under the influence of alcohol or might beassociated with alcohol dependence [41]. A review of
studies on of interventions to reduce alcohol problems
among ED- patients, found that interventions reduced al-
cohol related injuries [42]. Such interventions might be
effective if they were offered to alcohol positive injured
drivers.
The few single non-alcohol substances for which it was
possible to calculate risk estimates, were not statistically
significantly associated with accident risk, but combina-
tions of two or more such substances were. Some of
these substances are prescribed medicines and when pre-
scribing more than one psychoactive medicinal drug the
patient should be adequately informed about possible
risks associated with multiple psychoactive substance
use. Yet, it should also be noted that combined use of
several psychoactive substances, even prescription drugs,
may sometimes stem from illegal or informal sources.
Comparing oral fluid with blood samples gives more
accurate estimates of present impairment compared to
urine when using equivalent cut-off limits, and the use
of oral fluid is, therefore, recommended in future stud-
ies. As combinations of different psychoactive substances
were prevalent, one can not screen for just alcohol or
just THC, for example, and calculate the risk for these
substances. A full drug screen analysis is needed to en-
sure that a significant risk increase in one substance is
not due to combinations with other substances.
Conclusion
Prevalence of psychoactive substances was higher among
injured drivers than drivers in normal moving traffic. Al-
cohol and stimulant drugs were particularly prevalent
among drug positive injured drivers. The adjusted OR
was high for alcohol combined with drugs; for alcohol
alone, and for combinations of two or several non-
alcohol substances. Various preventive measures should
be considered to curb the prevalence of driving under
the influence of psychoactive substances as these drivers
constitute a significant risk for other road users as well
as themselves.
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